- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Abbreviated Radiotherapy Shows Promise in Prostate Cancer
Dramatically condensing radiation treatment for early prostate cancer into just 5 fractions produces good results without much toxicity, an early-phase study suggested. The hypofractionated schedule resulted in 99% biochemical and pathological control and only 1% experienced mild radiation side effects at 3 years, D. Andrew Loblaw, MD, of Sunnybrook Health Sciences Center in Toronto, and colleagues found.
Acute toxicity topped out at 1 case of grade 3 genitourinary problems among 83 patients treated, they reported here at the Genitourinary Cancers Symposium.
"That's a huge deal. Normal dosing is 40 to 45 fractions," Nicholas J. Vogelzang, MD, medical director of the developmental therapeutics committee of US Oncology, told MedPage Today. "Using accelerated hypofractionation, you can get what appear to be identical outcomes."
Not only would the once-weekly schedule with a total of only 5 radiation treatments used in the study be more convenient for patients, but it would likely substantially drop overall radiation costs, Vogelzang predicted.
Read more at: http://www.medpagetoday.com/MeetingCoverage/MGUCS/31020
Source: MedPage Today
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Obesity at Cancer Diagnosis Linked to Worse Survival Outcomes in Pediatric Patients
January 13th 2025Pediatric patients considered obese at cancer diagnosis are linked to significantly worse survival outcomes, especially those with acute lymphoblastic leukemia and central nervous system tumors.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
FDA Approves Tislelizumab-jsgr as First-Line Therapy for HER2– Gastric Cancers
January 2nd 2025Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic HER2-negative (HER–) gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose tumors express PD-L1.
Read More
